New hope for tough colon cancer: combo therapy targets BRAF mutation
NCT ID NCT07229846
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests a new immunotherapy drug (aipalolitovorelizumab) combined with standard chemotherapy and bevacizumab in 30 people with metastatic colorectal cancer that has a BRAF V600E mutation and is MSS/pMMR type. The goal is to see if the combination shrinks tumors and controls the disease longer. Participants will receive the drugs intravenously and orally in cycles, followed by maintenance therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aipalolitovorelizumab (QL1706) combined with bevacizumab and chemotherapy (oxaliplatin, irinotecan, fluorouracil, capecitabine)
What this could lead to
If successful, this could offer a new first-line treatment option for people with a hard-to-treat form of colorectal cancer that has spread.
What could go wrong
This is a small, early-phase study with only 30 participants and no comparison group, so results may not apply broadly. The combination therapy may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hosptital
Harbin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••